Oncotelic Files S-1/A for Mast Hill's 20.1% Share Resale Amid Going Concern Doubts

TL;DR

**OTLC is a highly speculative biotech facing massive dilution and a going concern warning; avoid this stock unless you're comfortable losing your entire investment.**

AI Summary

Oncotelic Therapeutics, Inc. (OTLC) filed an S-1/A on December 22, 2025, for the resale of 115,600,000 shares of common stock by Mast Hill Fund, LP, representing 20.1% of the company's outstanding shares. The shares stem from a Securities Purchase Agreement on July 31, 2025, and an Equity Purchase Agreement on August 1, 2025, including 100,000,000 shares from put notices, 3,350,000 from warrants, 8,000,000 from debt conversion, 2,000,000 from additional warrants, and 2,250,000 commitment fee shares. OTLC will not receive proceeds from Mast Hill's open market sales but will receive cash from put notices under the Equity Purchase Agreement. The company's independent registered public accounting firm has expressed substantial doubt about its ability to continue as a going concern. OTLC is a clinical-stage biopharmaceutical company focusing on orphan oncology indications and has formed a joint venture, GMP Biotechnology, Limited, with Dragon, affiliates of Golden Mountain Partners, LLC, in March 2022, which is contemplating an IPO. The last reported sales price for OTLC common stock on December 17, 2025, was $0.0940 per share.

Why It Matters

This S-1/A filing signals a significant potential dilution event for existing Oncotelic Therapeutics (OTLC) shareholders, as Mast Hill Fund, LP, a major investor, registers to resell 115,600,000 shares. The company's explicit 'going concern' warning from its auditors underscores severe financial instability, making any investment highly speculative. For employees, this raises questions about long-term viability, while customers and the broader market will view OTLC's drug development pipeline, including its JV with GMP Bio, with increased skepticism given the financial distress and the low stock price of $0.0940 per share. Competitively, this financial weakness could hinder OTLC's ability to advance its drug candidates against larger, better-capitalized biopharmaceutical firms.

Risk Assessment

Risk Level: high — The risk level is high due to the explicit statement from the independent registered public accounting firm expressing "substantial doubt as to our ability to continue as going concern." Additionally, the offering involves the potential resale of 115,600,000 shares by Mast Hill Fund, LP, which constitutes 20.1% of the Company's issued and outstanding common stock, indicating significant potential dilution for existing shareholders. The last reported sales price of $0.0940 per share on December 17, 2025, also reflects a highly speculative and volatile investment.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the 'going concern' warning and significant potential dilution from the Mast Hill resale, investors should avoid initiating a position or consider exiting existing positions to mitigate potential losses. Focus on companies with stronger financial health and clearer paths to commercialization.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$0

total Debt

$0

net Income

$0

eps

$0

gross Margin

N/A

cash Position

$0

revenue Growth

N/A

Key Numbers

• 115,600,000 — Shares of common stock for resale (May be offered by Mast Hill Fund, LP)
• 20.1% — Percentage of outstanding common stock (Represents the shares Mast Hill may sell relative to the fully diluted outstanding shares)
• $0.0940 — Last reported sales price per share (Oncotelic's common stock price on December 17, 2025)
• July 31, 2025 — Date of Securities Purchase Agreement (Agreement under which shares were transferred to Mast Hill)
• August 1, 2025 — Date of Equity Purchase Agreement (Agreement under which shares were transferred to Mast Hill)
• 100,000,000 — Shares from put notices (Issuable to Mast Hill under the Equity Purchase Agreement)
• 5,350,000 — Shares from warrant exercises (Total shares underlying warrants from both agreements)
• 8,000,000 — Shares from debt conversion (Issuable to Mast Hill upon conversion of indebtedness under the Note Purchase Agreement)
• 2,250,000 — Commitment Fee Shares (Issued to Mast Hill under the Note Purchase Agreement)
• March 2022 — Date of Joint Venture formation (Oncotelic entered into a JV with Dragon to form GMP Biotechnology, Limited)

Key Players & Entities

• Oncotelic Therapeutics, Inc. (company) — Registrant and clinical-stage biopharmaceutical company
• Mast Hill Fund, LP (company) — Selling Stockholder, deemed an 'underwriter'
• Vuong Trieu (person) — Chief Executive Officer of Oncotelic Therapeutics, Inc.
• James A Mercer III (person) — Legal counsel from Sheppard Mullin Richter & Hampton LLP
• Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• Dragon, affiliates of Golden Mountain Partners, LLC (company) — Joint venture partner with Oncotelic
• GMP Biotechnology, Limited (company) — Joint venture formed by Oncotelic and Dragon
• Autotelic, Inc. (company) — Granted exclusive license for AL-101 to Oncotelic
• OTCQB Market (company) — Market where Oncotelic's common stock is quoted
• BARDA (company) — Biomedical Advanced Research and Development Authority, with whom Oncotelic conducted an observational study

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's independent registered public accounting firm has expressed substantial doubt about Oncotelic Therapeutics, Inc.'s ability to continue as a going concern. This indicates significant financial instability and raises concerns about the company's long-term viability.
• Limited Trading Volume and Market Liquidity [medium — market]: Oncotelic's common stock is quoted on the OTCQB Market under the symbol 'OTLC', but there has been limited trading volume. The company warns that there is no guarantee an active trading market will develop, suggesting potential difficulties for investors in buying or selling shares.
• Significant Shareholder Resale [high — financial]: Mast Hill Fund, LP is offering to resell 115,600,000 shares, representing 20.1% of the company's outstanding stock. This large volume of shares being made available for sale could exert downward pressure on the stock price.
• Clinical Stage and Regulatory Approval Risk [high — regulatory]: As a clinical-stage biopharmaceutical company, Oncotelic's success is dependent on the successful development and regulatory approval of its drug candidates. Failure to obtain regulatory approval for any of its products would significantly impact its business and financial prospects.
• Dependence on Future Financing [high — financial]: The company's ability to fund its operations and clinical development programs is contingent on its ability to secure additional financing. The going concern warning suggests that such financing may be difficult to obtain on favorable terms, if at all.

Industry Context

Oncotelic Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically focusing on orphan oncology indications. This niche targets rare cancers, which may offer regulatory advantages but also presents challenges in patient recruitment for clinical trials and market size. The industry is characterized by long development cycles, high failure rates, and significant reliance on scientific innovation and regulatory approvals.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Oncotelic is subject to stringent regulatory oversight by bodies like the FDA. The success of its drug candidates hinges on navigating complex clinical trial processes and obtaining marketing approval. Any delays or failures in regulatory submissions or approvals pose significant risks to the company's business and financial outlook.

What Investors Should Do

1. Review 'Risk Factors' thoroughly.
2. Monitor trading volume and price action.
3. Assess the impact of Mast Hill's resale.
4. Evaluate the company's cash generation from 'Put Notices'.
5. Consider the joint venture's IPO plans.

Key Dates

• 2025-07-31: Securities Purchase Agreement — Agreement under which shares were transferred to Mast Hill Fund, LP, forming the basis for the current resale registration.
• 2025-08-01: Equity Purchase Agreement — Another agreement under which shares were transferred to Mast Hill Fund, LP, contributing to the large resale offering.
• 2025-12-17: Last Reported Sales Price — The common stock traded at $0.0940 per share, indicating a low market valuation.
• 2025-12-18: Outstanding Shares Calculation Date — Used to determine that the 115,600,000 shares represent 20.1% of the company's fully diluted outstanding shares.
• 2025-12-22: S-1/A Filing Date — Oncotelic Therapeutics, Inc. filed an amendment to its S-1 registration statement for the resale of shares by Mast Hill Fund, LP.
• 2022-03: Joint Venture Formation — Oncotelic formed GMP Biotechnology, Limited, with Dragon, which is contemplating an IPO, potentially impacting future company structure and value.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC. It is used to update or correct information previously filed on Form S-1. (This filing is an amendment to Oncotelic's S-1, indicating changes or additions to its initial registration for the resale of shares.)

Going Concern

A business assumption that a company will continue to operate for the foreseeable future. A 'substantial doubt' means there are significant uncertainties that could prevent the company from continuing operations. (The auditor's statement about substantial doubt regarding Oncotelic's ability to continue as a going concern is a critical warning about the company's financial health.)

Resale Prospectus

A prospectus filed by a company to allow existing shareholders to sell their shares to the public. The company does not receive proceeds from these sales. (This S-1/A is for the resale of shares by Mast Hill Fund, LP, meaning Oncotelic will not receive funds from these sales, though it will receive cash from specific put notices.)

Underwriter

An individual or firm that helps a company issue new securities and sells them to the public. In this context, Mast Hill Fund, LP is deemed an underwriter. (Mast Hill is considered an underwriter, which has implications for its role and potential liabilities in the resale of Oncotelic's shares.)

Put Notice

A notice given by an investor (in this case, Mast Hill) to a company, demanding that the company purchase or issue securities under the terms of a prior agreement. (Oncotelic will receive cash proceeds from Mast Hill pursuant to 'Put Notices' under the Equity Purchase Agreement, which is a source of cash for the company.)

Clinical-Stage Biopharmaceutical Company

A company focused on developing new drugs and therapies that are currently in the testing phases (clinical trials) before seeking regulatory approval. (This describes Oncotelic's business model, highlighting that its success is dependent on the outcomes of its research and development efforts and regulatory approvals.)

Orphan Oncology Indications

Cancer types that affect a small number of people, often referred to as rare cancers. Developing treatments for these can qualify for specific regulatory incentives. (This specifies Oncotelic's niche focus within the oncology market, suggesting a strategy to target less competitive areas with potential for expedited development.)

Commitment Fee Shares

Shares of stock issued to an investor as a fee for committing to a certain investment or agreement. (These 2,250,000 shares were issued to Mast Hill as a commitment fee, forming part of the total shares being registered for resale.)

Year-Over-Year Comparison

This S-1/A filing on December 22, 2025, primarily concerns the resale of a substantial number of shares by Mast Hill Fund, LP, which were acquired through various agreements in July and August 2025. Unlike a typical S-1 filing for a new offering, this document focuses on enabling an existing large shareholder to liquidate their position. The key financial metric highlighted is the last reported sales price of $0.0940 on December 17, 2025, which is extremely low. The filing reiterates the significant risk factor of substantial doubt about the company's ability to continue as a going concern, a critical concern for investors.

Key Financial Figures

• $0.01 — 0 shares of our common stock, par value $0.01 per share, which may be offered by Mast
• $0.0940 — ed sales price for our common stock was $0.0940 per share. We urge prospective purchase
• $25,000,000 — e. We may not have access to the full $25,000,000 amount of the Equity Purchase Agreement
• $250 m — ny and have a public float of less than $250 million, or annual revenues of less than
• $100 million — illion, or annual revenues of less than $100 million and no public float. As a smaller repor

Filing Documents

• forms-1a.htm (S-1/A) — 3368KB
• ex5-1.htm (EX-5.1) — 18KB
• ex23-1.htm (EX-23.1) — 3KB
• ex107.htm (EX-FILING FEES) — 32KB
• ex5-1_001.jpg (GRAPHIC) — 11KB
• 0001493152-25-028813.txt ( ) — 13019KB
• otlc-20250930.xsd (EX-101.SCH) — 79KB
• otlc-20250930_cal.xml (EX-101.CAL) — 56KB
• otlc-20250930_def.xml (EX-101.DEF) — 408KB
• otlc-20250930_lab.xml (EX-101.LAB) — 500KB
• otlc-20250930_pre.xml (EX-101.PRE) — 452KB
• forms-1a_htm.xml (XML) — 2276KB
• ex107_htm.xml (XML) — 5KB

Dilution

Dilution 24 Selling Security Holders 25 The Offering 27 Plan of Distribution 31 Description of Securities to be Registered 33 Legal Matters 35 Named Experts 35 Where You Can Find More Information 35 Description of Business 36 Description of Property 55 Legal Proceedings 56 Management's Discussion and Analysis of Financial Condition and Results of Operation 56 Directors, Executive Officers and Corporate Governance 70 Executive Compensation 72 Security 78 Certain Relationships and Related Transactions, and Director Independence 80 Shares Eligible for Future Sales 81 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure F-1 Financial F-1 Please read this prospectus carefully and in its entirety. This prospectus contains disclosure regarding our business, our financial condition and results of operations and risk factors related to our business and our common stock, among other material disclosure items. We have prepared this prospectus so that you will have the information necessary to make an informed investment decision. You should rely only on information contained in this prospectus. We have not authorized any other person to provide you with different information. This prospectus is not an offer to sell, nor is it seeking an offer to buy, these securities in any state where the offer or sale is not permitted. The Selling Stockholder may not sell the securities listed in this prospectus until the registration statement filed with the Securities and Exchange Commission is effective. The information in this prospectus is complete and accurate as of the date on the front cover, but the information may have changed since that date. The registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and ou

View Full Filing

View this S-1/A filing on SEC EDGAR